Literature DB >> 7226474

Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease.

R G Pozen, R DiBianco, R J Katz, R Bortz, R J Myerburg, R D Fletcher.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7226474     DOI: 10.1161/01.cir.63.6.1279

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

1.  Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease.

Authors:  H Pouleur; C van Eyll; J Etienne; H van Mechelen; A Vuylsteke; M F Rousseau
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 2.  Inotropic agents in the treatment of cardiogenic shock.

Authors:  H S Mueller
Journal:  World J Surg       Date:  1985-02       Impact factor: 3.352

3.  [Early hemodynamic effects of olprinone hydrochloride after coronary artery bypass grafting].

Authors:  A Marui; T Mochizuki; N Mitsui; T Koyama; M Horibe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-11

4.  Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat, and digoxin.

Authors:  H N Sabbah; T B Levine; M Gheorghiade; T Kono; S Goldstein
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 5.  Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure.

Authors:  I Crozier; H Ikram
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 6.  Cardiac efficiency.

Authors:  J D Schipke
Journal:  Basic Res Cardiol       Date:  1994 May-Jun       Impact factor: 17.165

7.  Differential effects of OPC-18790, amrinone and dobutamine on cardiac function and energy metabolism in the guinea-pig isolated ischaemic heart.

Authors:  S Itoh; T Mori; M Tominaga; M Ishikawa; K Koga; Y Yabuuchi
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.